Osimert 80 mg (Generic Osimertinib) – Everest Pharmaceuticals

Osimert 80 mg is a generic formulation of Osimertinib — a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI) — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 80 mg of osimertinib, the same active molecule found in Tagrisso® (AstraZeneca), and is dispensed under the Named Patient Program for patients requiring a quality-assured, affordable alternative.

Osimertinib is uniquely effective both as a first-line treatment for EGFR-mutated NSCLC and as a second-line treatment after resistance to earlier-generation EGFR inhibitors via the T790M mutation. It also has the strongest CNS penetration of any approved EGFR inhibitor.

In EGFR-mutated NSCLC, mutations such as exon 19 deletions or L858R cause the EGFR receptor to become permanently switched on, driving uncontrolled tumour growth. Osimertinib selectively and irreversibly binds to mutant EGFR, including the T790M resistance mutation that commonly emerges after treatment with first- or second-generation EGFR inhibitors.

Osimertinib is generally one of the better-tolerated targeted therapies, with a milder side-effect profile than earlier EGFR inhibitors. Most patients adjust well within the first month.

• Week 1: Many patients feel relatively normal initially, though mild fatigue is common as your body adjusts to the new daily dose.
• Weeks 2–3: Skin changes — dry skin or a mild acne-like rash — commonly emerge during this window, along with a possible mild decrease in appetite. These are usually manageable with supportive skin care.
• Week 4: Your body has generally adjusted to the routine by now. Your oncologist will typically schedule a check-in to review side effects and discuss early imaging to assess response.

Osimertinib is generally well-tolerated, with most side effects mild and manageable. Always report new or worsening symptoms to your oncologist promptly.

Standard dose: 1 tablet (80 mg) once daily, with or without food.

• 1
  Once daily at the same time — consistency improves steady-state drug levels.
• 2
  Swallow tablet whole with a glass of water. Do not chew or crush.
• 3
  If swallowing is difficult: drop the tablet into a small glass of plain (non-carbonated) water — do not crush or chew it — stir until it disperses, then drink immediately. Rinse the glass with a little more water and drink that too, to ensure the full dose is taken.
• 4
  Never stop without your oncologist’s instruction — discontinuing without guidance risks rapid disease progression.
• 5
  Storage: below 30°C, protected from moisture and light, out of reach of children.

• ♥
  Track side effects in a simple journal — especially skin rashes and diarrhoea — so you can report them accurately at appointments.
• ♥
  Monitor breathing closely — pay attention to any new shortness of breath or persistent cough and contact the oncologist if you notice changes.
• ♥
  Support daily adherence — set a phone alarm or use a pill organiser to make sure a dose is never missed.